Cipher Pharmaceuticals (DND.TO) Receives FDA Response to CIP-TRAMADOL ER Appeal  
2/1/2008 3:18:00 PM

MISSISSAUGA, ON, Feb. 1 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND) today announced that it has received a written response from the U.S. Food and Drug Administration (FDA) regarding its appeal of the Agency's Approvable Letter for CIP-TRAMADOL ER, Cipher's extended-release formulation of tramadol. In the response, the Acting Director of the Office of Drug Evaluation II, Center for Drug Evaluation and Research supported the Division's approvable action.